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Abstract
Recurrent submicroscopic deletions in genes affecting key cellular pathways are a hallmark of pediatric acute lymphoblastic
leukemia (ALL). To gain more insight into the mechanism underlying these deletions, we have studied the occurrence and
nature of abnormalities in one of these genes, the B-cell translocation gene 1 (BTG1), in a large cohort of pediatric ALL cases.
BTG1 was found to be exclusively affected by genomic deletions, which were detected in 65 out of 722 B-cell precursor ALL
(BCP-ALL) patient samples (9%), but not in 109 T-ALL cases. Eight different deletion sizes were identified, which all clustered
at the telomeric site in a hotspot region within the second (and last) exon of the BTG1 gene, resulting in the expression of
truncated BTG1 read-through transcripts. The presence of V(D)J recombination signal sequences at both sites of virtually all
deletions strongly suggests illegitimate RAG1/RAG2-mediated recombination as the responsible mechanism. Moreover,
high levels of histone H3 lysine 4 trimethylation (H3K4me3), which is known to tether the RAG enzyme complex to DNA,
were found within the BTG1 gene body in BCP-ALL cells, but not T-ALL cells. BTG1 deletions were rarely found in
hyperdiploid BCP-ALLs, but were predominant in other cytogenetic subgroups, including the ETV6-RUNX1 and BCR-ABL1
positive BCP-ALL subgroups. Through sensitive PCR-based screening, we identified multiple additional BTG1 deletions at the
subclonal level in BCP-ALL, with equal cytogenetic distribution which, in some cases, grew out into the major clone at
relapse. Taken together, our results indicate that BTG1 deletions may act as ‘‘drivers’’ of leukemogenesis in specific BCP-ALL
subgroups, in which they can arise independently in multiple subclones at sites that are prone to aberrant RAG1/RAG2-
mediated recombination events. These findings provide further evidence for a complex and multiclonal evolution of ALL.
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Introduction
Acute lymphoblastic leukemia (ALL) is the most common form
of cancer in children, and can be subdivided in T-lineage leukemia
(T-ALL) and B-cell precursor leukemia (BCP-ALL). BCP-ALL
makes up about 80% of all pediatric ALL cases, and comprises
genetically distinct subtypes. These ALL subtypes are character-
ized by specific genetic abnormalities, including aneuploidies
(hyperdiploidy and hypodiploidy) and chromosomal translocations
leading to ETV6-RUNX1, E2A-PBX1, BCR-ABL1, and MLL gene
fusions [1]. An additional layer of complexity was recently
revealed by the identification of recurrent copy number alterations
(CNAs), including single gene deletions [2–4], some of which are
strongly associated with disease progression and outcome [5–7].
Despite the high number of CNAs that has been identified in BCP-
ALL, the total number of structural genetic lesions in each
individual leukemia sample is usually limited to less than 10 per
case. A subset of these genetic lesions, predominantly single gene
deletions, may act as ‘drivers’ in the development of BCP-ALL.
Genes commonly affected by these driver deletions function in key
pathways such as cell cycle regulation (CDKN2A, CDKN2B, RB1),
lymphoid development (PAX5, EBF1, IKZF1, RAG1/2), and
nuclear hormone receptor signaling (NR3C1, TBL1XR1).
One of the newly identified players in BCP-ALL is the B cell
translocation gene-1 (BTG1) [4,8]. BTG1 belongs to the BTG/TOB
family of anti-proliferative genes (BTG1-BTG4, TOB1 and TOB2)
and expression of their gene products is altered in a variety of
different cancers [9]. The BTG1 gene has been reported to be
affected by deletions in approximately 10% of the BCP-ALL cases
[2,3], and to be targeted by nonsense and missense point
mutations in diffuse large B-cell lymphoma [10]. BTG1 was
shown to directly interact with multiple transcription factors and
modulators involved in the regulation of crucial cellular processes
including mRNA turnover and histone modification [11–14].
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glucocorticoid receptor (GR)-dependent transcriptional response
in leukemic cells [8], which turns this gene into an interesting
target for modulating therapy response.
Several recurrent chromosomal abnormalities in leukemia show
a clustering of their breakpoints, suggesting that features intrinsic
to the DNA may underlie their origin. A common mechanism
underlying these abnormalities is non-homologous end joining
(NHEJ). NHEJ is employed by human cells to repair DNA double
strand breaks caused by external damage or by intermediate steps
of V(D)J recombination and class switch recombination (CSR)
events during lymphocyte development [15–17]. The RAG
complex mediates V(D)J recombination through the recognition
of recombination signal sequences (RSS) located directly adjacent
to the V, D, or J segments, thereby generating the variability of
immunoglobulins (Ig) as well as B- and T-cell receptors.
Illegitimate RAG-mediated recombination has been proposed to
be involved in the translocation process of the LMO2 and TAL1
proto-oncogenes with TCRd [18], and appears to be the cause of
recurrent intragenic deletions of the IKZF1 gene in BCP-ALL and
lymphoid blast crisis in chronic myeloid leukemia (CML) [19,20].
Comprehensive genomic analyses of relapsed BCP-ALL have
revealed that diagnosis and relapse samples are clonally related,
but may exhibit subtle differences, frequently involving lesions
detected at the time of diagnosis that are absent at the time of
relapse [5,21,22]. Furthermore, diagnosis and relapse samples may
carry alternative lesions affecting genes like e.g. CDKN2A and
PAX5, suggesting that these lesions occur repeatedly during clonal
evolution of BCP-ALL [5]. These findings are in line with the
generally accepted concept that each leukemic outgrowth
comprises a heterogeneous population of leukemic cells of which
only a subset has the potential to drive progression of the disease,
survive therapy, and/or induce relapse development [23]. Recent
studies in BCP-ALL have revealed that this multiclonal architec-
ture supports a complex model of multiclonal evolution [24,25].
During disease progression and after post-treatment relapse, shifts
can occur in the dominance of leukemic subclones, most likely
triggered by new selective bottlenecks, whereas the subclonal
diversity appears to be maintained.
In the present study, we have characterized the origin and
nature of BTG1 deletions in a cohort of 831 pediatric ALL cases.
We demonstrate that BTG1 deletions are exclusively found in
BCP-ALL, both in the predominant clone and in (multiple) minor
subclones, and are strongly associated with ETV6-RUNX1 and
BCR-ABL1 positive ALL, but rare in hyper-diploid cases.
Furthermore, we show that these deletions most likely arise from
illegitimate RAG-mediated recombination, are tightly clustered,
and virtually all share their telomeric breakpoint within the second
exon of BTG1, resulting in the expression of a read-through
transcript that gives rise to highly instable truncated BTG1
protein. These results provide important insight into the
mechanism underlying the occurrence of BTG1 deletions in
BCP-ALL and support the recently observed complexity of
multiclonal evolution of ALL.
Results
BTG1 Is Targeted by Deletions in Specific Subsets of BCP-
ALL
We screened 831 pediatric ALL diagnosis samples for copy
number aberrations in BTG1 (Entrez Gene: 694) using multiplex
ligation-dependent probe amplification (MLPA). In 722 BCP-ALL
samples, we found a total of 65, predominantly monoallelic,
deletions (9%), whereas no BTG1 copy number loss was detected
in any of the T-ALL samples (n=109; P=0.001; Table 1). In
addition, MLPA performed on genomic DNA derived from BCP-
ALL (n=10) and T-ALL (n=5) cell lines revealed BTG1 deletions
in the BCP-ALL cell lines REH, SUP-B15, MUTZ5 and 380,
while none could be detected in the T-ALL cell lines (see Materials
and Methods). Sequencing of the entire gene in 135 BCP-ALL
cases and of exon 2, which contains the major body of the open
reading frame, in 158 additional BCP-ALL cases and 44 T-ALL
cases revealed no mutations. Furthermore, bisulfite sequence
analysis showed absence of BTG1 promoter hypermethylation in
20 BCP-ALL and 5 T-ALL cases.
BTG1 deletions were found to be unevenly distributed between
the different cytogenetic subgroups, being enriched in ETV6-
RUNX1 (TEL-AML1) and BCR-ABL1 positive cases, and less
frequent in hyperdiploid cases (P,0.001, P=0.003 and P=0.002,
respectively; Table 1). In addition, targeted copy number analysis
of recurrently affected genes in ALL revealed that cases with BTG1
deletions more frequently harbored deletions of ETV6, RB1 and
EBF1 (P=0.007, P,0.001 and P,0.001 respectively; Table S1).
Together, our data indicate that BTG1 is affected by deletions in
specific subsets of pediatric BCP-ALL patients.
A Deletion Breakpoint Hotspot Maps within the Second
Exon of BTG1
To further define the size and location of the BTG1 deletions,
SNP-based genomic profiling was performed on 24 BTG1
deletion-positive BCP-ALL diagnosis samples and the BCP-ALL
derived cell lines REH, SUP-B15, and 380. In nearly all cases, the
telomeric deletion breakpoint was located within the BTG1 gene.
Subsequent PCR-based fine-mapping and direct sequencing
revealed that the intragenic breakpoints tightly clustered within
a region of 33 base pairs in the second (and last) exon of BTG1,
with the majority (75%) of the breakpoints being located within a
stretch of 10 base pairs (Figure 1A, Table S2). The centromeric
breakpoints mapped to 8 different positions downstream of the
BTG1 gene, resulting in deletions ranging in size from 101 to
557 kb (deletions I-VIII). This highly specific clustering of deletion
breakpoints allowed us to perform a PCR-based screening of all 65
BCP-ALL diagnosis samples. Hence, we were able to exactly map
the deletions in 52 of the 65 cases and found that deletion III was
most prevalent, comprising almost half of all lesions identified
(49%). Deletions V and VIII were found in 15 and 17% of the
Author Summary
Recent studies have alluded to the existence of a complex
clonal cellular architecture in acute lymphoblastic leuke-
mia (ALL), where multiple subclones contribute to
leukemogenesis. Here, we show that in pediatric B-cell
precursor ALL (BCP-ALL) monoallelic deletions in the
tumor suppressor BTG1 locus, which were found to occur
in 9% of the patients studied, result in truncations of the
gene rather than in complete allelic losses. Using both
genetic and epigenetic approaches, we show that these
deletions most likely originate from illegitimate RAG
recombination. Sensitive backtracking using deletion-
spanning PCRs revealed that these BTG1 deletions occur
in specific BCP-ALL subtypes, with frequencies higher than
previously anticipated, often in one minor subclone or in
multiple independent subclones within individual patients.
Subclones that carry a BTG1 deletion at diagnosis can
evolve into the major clone at relapse. These findings link a
mechanism of tumor suppressor gene deletion to the
multiclonal evolution of ALL.
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degree of clustering of BTG1 deletion breakpoints in BCP-ALL.
Subclones with Distinct BTG1 Deletions Frequently Arise
in BCP-ALL Subtypes
Remarkably, while validating the BTG1 deletions with break-
point-spanning PCRs, multiple BTG1 deletions were identified in
18 of the 65 deletion positive cases (27%), all of which turned out
to be monoallelic losses using MLPA. The individual deletions
appeared to be unique in their exact breakpoints and flanking
interstitial sequences (Table S2), thus indicating the presence of
multiple subclones which independently acquired BTG1 deletions.
In one patient, as many as 4 unique deletions were identified
(Figure 2A, Table S3). Triggered by this finding we performed a
similar PCR-based BTG1 deletion screening for the three most
common deletions (III, V, and VIII) in 89 deletion negative BCP-
ALL cases as scored by MLPA or SNP array and were able to
confirm the presence BTG1 deletions in minor subclones in 16
cases (18%), which is substantially more frequent than the
occurrence of this abnormality in the predominant leukemic clone
(Figure 2B). Similar to the previously observed clonal BTG1
deletions, these subclonal events were detected in several ETV6-
RUNX1–positive cases and not in the hyperdiploid subgroup
(Figure 2B, Table S4). Furthermore, no subclonal BTG1 deletions
were detected in 77 T-ALL cases nor in 26 bone marrow samples
from healthy volunteers. Together, we conclude that BTG1
deletions are associated with specific BCP-ALL subtypes where
they can repeatedly arise in independent subclones.
BTG1 Deletion (Sub)Clones May Reoccur in Relapse
To examine whether minor subclones or progenitors thereof
that harbor a BTG1 deletion can evolve into relapse clones, we
analyzed 62 matched relapse samples using MLPA for focal BTG1
deletions. All deletion-positive cases were subjected to breakpoint-
spanning PCR for each of the eight deletion variants (deletions I–
VIII). Again, we found unique BTG1 deletions both in the
predominant clone and/or in (multiple) subclones (Table 2). An
additional deletion was sequenced of which the telomeric break-
point is located 2 kb downstream in the 39UTR of BTG1.
Backtracking and sequencing of the deletion breakpoints in
matched diagnosis samples revealed that these BTG1 deletion
clones originated from a (sub)clone at diagnosis in at least four
cases. These data confirm that BTG1 deletions arise repeatedly
and independently during disease progression and that these
leukemic (sub)clones frequently reoccur at relapse.
Truncated BTG1 Transcripts Are Expressed in BCP-ALLs
with BTG1 Deletions
Virtually all deletions affecting the BTG1 locus target the second
exon of BTG1, leaving the possibility of expression of a truncated
Table 1. BTG1 microdeletion occurrence within cytogenetic subgroups of ALL.
Number of Samples
a
BTG1 deletion positive
cases (%)
BTG1 deletion negative
cases (%) P-value Chi-square
T-ALL 109 0 (0) 109 (100) 0.001
BCP-ALL 722 65 (9.0) 657 (91.0)
Cytogenetic subgroup ,0.001
Hyperdiploid (.50chr) 0.002
Yes 160 5 (3.1) 155 (96.9)
No 477 55 (11.5) 422 (88.5)
ETV6-RUNX1 ,0.001
Yes 142 27 (19.0) 115 (81.0)
No 371 22 (5.9) 349 (94.1)
BCR-ABL1 0.003
Yes 23 6 (26.1) 17 (73.9)
No 625 52 (8.3) 573 (91.7)
MLL rearranged 0.385
d
Yes 17 0 (0) 17 (100)
No 632 55 (8.7) 577 (91.3)
Other subgroup
b 0.155
Yes 180 13 (7.2) 167 (92.8)
No 342 38 (11.1) 304 (88.9)
Subgroup unknown
c 0.245
Yes 200 14 (7.0) 186 (93.0)
No 522 51 (9.8) 471 (90.2)
BTG1 deletion status was determined using MLPA.
aBecause of missing values, numbers do not always add up to 722 BCP-ALL cases. Data was available for 637 cases on hyperdiploidy; 513 cases for ETV6-RUNX1; 648
cases for BCR-ABL1; 649 cases for MLL-rearranged.
bThe ‘other’ subgroup encompasses cases negative for ETV6-RUNX1 or BCR-ABL1 translocations, MLL-rearrangement and/or hyperdiploidy. This group includes 10 cases
with E2A-PBX1 translocation, of which none harbor a BTG1 deletion.
cSubgroup unknown includes all cases in which no data is available in one or more cytogenetic classifications.
dFisher’s exact test was used when sample groups were small.
doi:10.1371/journal.pgen.1002533.t001
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was expressed from the rearranged allele, RT-PCR using break-
point-flanking primers was performed on three BCP-ALL cell lines
with a BTG1 deletion (380, REH and SUP-B15 with deletions II,
III and IV, respectively) and two cell lines that are BTG1 deletion
negative (Nalm6 and RS4;11) (Figure 3). Wild-type BTG1 mRNA
was found to be present in all cell lines, whereas truncated read-
through transcripts specific for each type of deletion could be
detected only in the three deletion positive BCP-ALL cell lines
(Figure 3B). Similarly, we detected BTG1 read-through transcripts
in primary BCP-ALL samples with BTG1 deletions III, V and
VIII, respectively, several of which could be confirmed on
genomic DNA of these patients (Figure 3C). Notably, the presence
of multiple BTG1 deletion subclones as observed at the genomic
level was also detectable at the transcript level and subsequent
sequencing confirmed the unique identity of each clone (Table S5).
Quantitative RT-PCR revealed that in REH, SUP-B15 and 380
cells the rearranged BTG1 allele was expressed at significantly
higher levels compared to the wild-type BTG1 allele, which may
reflect differences in mRNA stability (Figure 3D). These results
indicate that monoallelic BTG1 deletions result in the expression of
truncated BTG1 transcripts, encoding more than half of the BTG1
protein.
To assess the function of the truncated BTG1 protein, a C-
terminal deletion variant of BTG1, which terminates at the
common breakpoint after amino acid residue 100, was cloned in
vector pcDNA3.1 and tested for protein expression. For
comparison, wild-type BTG1 was included in the analyses (Figure
Figure 1. BTG1 deletions cluster tightly and disrupt the BTG1 open reading frame. (A) The BTG1 gene located on the antisense strand of
chromosome 12q22 is exclusively disrupted by deletions (indicated by black bars). We identified 8 different deletions ranging from 101 to 557 kb in
size. The deletion breakpoints cluster tightly within exon 2, the majority of which are located within a stretch of 10 base pairs. Colored triangles
indicate the position of the breakpoints in different patients. Light blue represents the breakpoint of deletion I, grey deletion II, blue deletion III, pink
deletion IV, purple deletion V, green deletion VI, red deletion VII and orange deletion VIII, respectively. The exact BTG1 deletion breakpoint sequences
are listed in Table S2. Chromosomal location refers to human GRCh37/hg19 genome assembly. (B) In our cohort of 65 deletion positive BCP-ALL
cases, as determined by MLPA, we detected eight distinct deletions with different frequencies. Deletion III was most prevalent (49% of the cases).
doi:10.1371/journal.pgen.1002533.g001
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proteosomal degradation [8], but in the presence of proteosome
inhibitor MG132, expression could be readily detected (Figure
S1B). In contrast, truncated BTG1 (HA-BTG1-Trunc) protein
levels appeared to be highly unstable and hardly detectable even in
the presence of MG132 (Figure S1B), while mRNA expression
levels were equal to those of full-length HA-BTG1 (Figure S1C).
Based on these findings, we conclude that the read-through
transcripts that are expressed upon focal loss of BTG1, are unlikely
to give rise to functionally active protein, which favors a BTG1
haploinsufficiency scenario.
BTG1 Deletions May Result from Illegitimate RAG-
Mediated Recombination
Because illegitimate RAG-mediated recombination has been
implicated in the origin of several translocations and deletions in
leukemia [18–20], we examined the sequences flanking each of the
BTG1 breakpoints for the presence of recombination signal
sequences (RSS). RSS motifs represent moderately conserved
heptamer (CACAGTG) and nonamer (ACAAAAACC) sequences
separated by either a spacer of 1261 bp (12-RSS) or a spacer of
2361 bp (23-RSS). The RAG complex only joins gene segments
containing RSSs with different spacer lengths, complying to the
12/23 rule for efficient V(D)J recombination (Figure S2). Notably,
we found that a 23-RSS was present at the recombination hotspot
in the second exon of BTG1, while all but one of the centromeric
breakpoints were found to harbor a 12-RSS (Table 3; Table S2).
Furthermore, all deletion breakpoints contained a random
addition of single nucleotides between the joining ends, which is
most likely due to the action of terminal deoxynucleotidyl
transferase (TdT). Together, these findings strongly support a role
for illegitimate RAG-mediated recombination in the occurrence of
BTG1 deletions.
The BTG1 Gene Exhibits Elevated H3K4me3 Levels in B-
Lineage Cells
Recent studies have shown that RAG-mediated V(D)J recom-
bination is controlled by histone modifications, including histone
H3 and H4 acetylation and H3 trimethylation, that are normally
present at promoter regions of actively transcribed genes [26,27].
More specifically, it has been demonstrated that the RAG2 plant
homeodomain (PHD) finger binds directly to H3K4me3, thereby
stimulating the catalytic activity of the RAG enzyme complex
[28]. To reveal whether differences in levels of H3K4 trimethyla-
tion and/or H3K9/14 acetylation could explain the lineage-
specific occurrence of BTG1 deletions, chromatin immunoprecip-
itation (ChIP) experiments were performed targeting different
positions within the BTG1 gene in several B-lineage and T-lineage
cell lines exhibiting abundant BTG1 expression (Figure 4A). As
expected, prominent levels of H3K4me3 were present at the
proximal promoter region close to the transcription start site in
both B-lineage and T-lineage cell lines (Figure 4B). In contrast,
only BCP-ALL cell lines displayed significantly higher levels of
H3K4me3 near the breakpoint hotspot within the second exon of
BTG1. H3K9/14 acetylation levels were found to significantly
differ at the proximal promoter region between B- and T-lineage
cells, but not at the body of the BTG1 gene (Figure 4C). In
conclusion, our data suggest that illegitimate RAG-mediated
recombination at the deletion breakpoint hotspot within the
second exon of BTG1 in B-lineage cells may be facilitated by
increased levels of H3K4me3.
Discussion
In this study, we demonstrate that BTG1, a recurrent target in
pediatric ALL, is affected by gene truncating deletions, which
occur predominantly in two cytogenetic subgroups of pediatric
Table 2. BTG1 deletions in relapsed cases.
Case
Relapse
(MLPA) Relapse (PCR)
Diagnosis
(MLPA)
Diagnosis
(PCR) Backtracking of relapse clone in diagnosis sample
a
BCP-ALL 1078 deletion III, IV normal III two new events
BCP-ALL 1174 deletion III normal III match diagnosis and relapse
BCP-ALL 1193 deletion IV normal N.D.
b one new event
BCP-ALL 1236 deletion N.D.
b normal N.D.
b -
BCP-ALL 1405 deletion III, VIII normal III, VIII two new events
BCP-ALL 1086 deletion VI deletion VI match diagnosis and relapse
BCP-ALL 1176 deletion N.D.
b deletion N.D.
b -
BCP-ALL 1304 deletion III, VIIIb
c deletion VIIIb
c new event + match diagnosis and relapse
BCP-ALL 1273 deletion
d N.D.
b deletion III new event
aDetermined by sequence analysis of breakpoint spanning PCR product.
bThe deletion breakpoint could not be detected (N.D.) using the eight breakpoint-spanning PCR assays (I–VIII).
cThe breakpoint does not cluster within BTG1 exon 2, but is located 2 kb downstream in the 39UTR.
dHomozygous deletion.
doi:10.1371/journal.pgen.1002533.t002
Figure 2. Multiple BTG1 deletion-positive clones are present in specific BCP-ALL subtypes. (A) Recurrence of multiclonal BTG1 deletions. A
sensitive PCR method was used to screen for eight different deletion breakpoints (deletion I–VIII) in BTG1 MLPA deletion positive (+) cases (n=65),
and to screen for the three most frequent deletion breakpoints (deletion III, V and VIII) in BTG1 MLPA deletion negative (2) cases (n=89). (B) BTG1
deletion frequency in the two major cytogenetic subgroups of BCP-ALL (Hyperdiploid and ETV6-RUNX1). Presence of a BTG1 deletion in the
predominant clone was determined by MLPA on the entire cohort of BCP-ALL cases (n=722), and was compared to deletions detected as a minor
clone in MLPA-negative cases (n=89) by deletion-spanning PCR. Distributions are similar, being depleted from hyperdiploid cases and enriched in
ETV6-RUNX1-positive cases as compared to the total group.
doi:10.1371/journal.pgen.1002533.g002
Tightly Clustered BTG1 Deletions in BCP-ALL
PLoS Genetics | www.plosgenetics.org 6 February 2012 | Volume 8 | Issue 2 | e1002533Figure 3. Expression of BTG1 truncated read-through transcripts in BCP-ALL cells with BTG1 deletions. (A) Schematic representation of
the wild-type human BTG1 gene, existing of two partly coding exons, and five different BTG1 transcripts due to BTG1 gene deletions. Exons are
represented by black (coding) or white (non-coding) bars. Indicated are the RT-PCR primers that were used to detect expression of the wild-type BTG1
transcript (primers A and B), or one of the BTG1 truncated read-through transcripts for deletion II (primers A and C), deletion III (pimers A and D),
deletion IV (primers A and E), deletion V (primers A and F), or deletion VIII (primers A and G). (B) RT-PCR analyses on total RNA isolated from the BCP-
ALL cell lines Nalm6 and RS4;11 (BTG1 wild-type) and REH, SUP-B15 and 380, each with distinct monoallelic BTG1 deletions. (C) RT-PCR analyses on
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positive (26%) subgroups. Within these subgroups, BTG1 deletions
frequently arise independently in different subclones, which is in
full conformity with the recently reported complex multi-clonal
evolution model of ALL [24,25]. In addition, our results suggest a
role for BTG1 deletions in the clonal selection and outgrowth in
these BCP-ALL subgroups.
Through high-resolution genomic profiling, BTG1 was only
recently identified as a recurrent target in pediatric ALL [2–4].
Here we demonstrate, using a cohort of 831 pediatric ALL cases,
that BTG1 is targeted by a restricted number of well-demarcated
genomic deletions. These microdeletions were found predomi-
nantly as monoallelic events at the clonal level in about 9% of the
BCP-ALL cases, and were found to be completely absent in the T-
ALL cases studied. Promoter hypermethylation events or sequence
mutations were not detected. In contrast, BTG1 mutations have
frequently been found in diffuse large B-cell lymphoma, arguing
that other mutation mechanisms may target BTG1 in more
maturated B-lineage malignancies [10]. Eight different deletions in
52 cases were molecularly cloned and sequenced. Together, the
three most prevalent deletions (III, V and VIII) were found in 81%
of the total. Of note, the vast majority of telomeric BTG1 deletion
breakpoints were found to be tightly clustered within a stretch of
10 bp in the last exon of BTG1.
This remarkable finding has both structural and functional
implications. Structurally, this breakpoint clustering implies the
presence of sequence features underlying the origin of BTG1
deletions. Virtually all breakpoints that were mapped, including
those within exon 2, were flanked by non-canonical RSS
sequences, which strongly suggests that they have arisen from
illegitimate RAG-mediated recombination. In line with these
observations, BCP-ALL derived cell lines showed local accumu-
lation of H3K4me3 within the coding region of the BTG1 gene
including the second exon, which harbors the breakpoint hotspot.
This epigenetic mark is normally associated with the proximal
promoter of actively transcribed genes and, in addition, has been
shown to act as a docking site for RAG2 binding, thereby
facilitating V(D)J recombination [28]. In contrast, in T-ALL-
derived cell lines these H3K4me3 marks were not enriched at the
site of the BTG1 gene body, which indicates that in these cells the
locus is less accessible for the RAG enzyme complex. Illegitimate
recombination events at cryptic RSS motifs have been implicated
in several recurrent chromosomal abnormalities in lymphoid
malignancies, such as translocations and deletions. For example,
both ETV6-RUNX1 and BCR-ABL1 translocations have been
suggested to arise from mistargeting of RAG proteins that facilitate
RAG-mediated transposition or at least create one of the initiating
lesions in the form of nicks [29–31]. This mistargeting of RAG
proteins may occur as a rare spontaneous event during lymphocyte
differentiation, but may also result from increased or prolonged
RAG activity in leukemic lymphoid blasts. This latter phenom-
enon may explain the subtype specificity of BTG1 deletions and/or
the co-occurrence of these deletions with ETV6-RUNX1 and BCR-
ABL1 translocations.
The recurrence of truncating BTG1 deletions in BCP-ALL may
also point towards a functional role in leukemogenesis. BTG1
belongs to the BTG/TOB family of anti-proliferative genes (BTG1-
BTG4, TOB1 and TOB2) implicated in several types of cancer [9].
We recently reported that in BCP-ALL, BTG1 regulates the
glucocorticoid receptor (GR)-dependent transcriptional response
in leukemia cells, while loss of BTG1 expression leads to
glucocorticoid resistance in cell line models [8]. In addition, we
have shown that leukemia clones carrying BTG1 deletions can
survive therapy and rearise as a predominant clone in relapse or,
as shown also by others, can occur as new lesions in relapse
[21,32]. Many BTG1 deletions result in almost identical
truncations of the open reading frame and the consequent loss
of two conserved C-terminal protein interaction domains.
Nevertheless, dominant-negative or gain-of-function effects of the
truncated BTG1 protein are less likely since the truncated BTG1
protein appears to be highly unstable. Furthermore, we also
encountered deletions encompassing the entire open reading
frame or only part of the 39-UTR, indicating that truncation of the
BTG1 open reading frame is highly frequent but not essential.
The fact that BTG1 deletion breakpoints are tightly clustered
provides an opportunity to perform rapid and sensitive deletion
screening through breakpoint-spanning PCRs. By applying this
screening approach to our pediatric ALL cohort we identified,
besides the most prominent BTG1 deletions, additional deletions in
a substantial fraction (18%) of BCP-ALL cases at the subclonal
level. These deletions remained undetected using standard
procedures like MLPA or SNP arrays. In several cases, multiple
deletions co-occurred in a single patient, each carrying unique
breakpoint-spanning sequences that were detectable both at the
genomic and at the transcript level. Analogous to the most
Table 3. Authentic RSSs and candidate RSSs flanking
breakpoints of BTG1 microdeletions.
RSS Heptamer Spacer Nonamer
Optimal consensus CACAGTG ACAAAAACC
VkA27
a CACAGTG 12 ACAAAAACC
Jk1
a CACAGTG
b 23 ACAAAAACC
TAL2 (9q32)
c CACTGTG
b 13 ATAAAAATA
LMO2 (11p13)
c CACAGTA
b 12 GCAATAATT
BTG1 exon 2 CACTCTG 23 ACAGAATTG
Deletion I CACAGTA
b 12 CCAGGACAT
Deletion III CACAATG
b 13 ACTGAAATG
Deletion IV CACAGCT
b 12 ACATTTTCA
Deletion V CACTGCA
b 12 GCAATAACC
Deletion VI CACAGAG
b 13 ACAATATAG
Deletion VII CACTGTG
b 12 ATATATTCT
Deletion VIII CACAGTG
b 12 ACAATTAAT
Mismatches from consensus are underlined;
aRSSs flanking V(D)J gene segments;
bSequence shown is in reverse complement orientation;
cFunctional cryptic RSSs at proto-oncogene breakpoints [18].
doi:10.1371/journal.pgen.1002533.t003
primary BCP-ALL samples in which a single BTG1 deletion (Pt1, Pt2, Pt3 and Pt5), multiple BTG1 deletions (Pt4 and Pt6) or no BTG1 deletions were
detected with genomic PCR (Pt7). Type of deletions (III, V, or VIII) and outcome of MLPA (p: deletion-positive; n: deletion-negative) are indicated. BTG1
read-through transcripts were verified by sequencing (Table S5), except for Pt3-deletion V, which was an unrelated DNA sequence. (D) Quantitative
real-time RT-PCR data representing relative expression levels of BTG1 measured 59 (primers exon 1/2) and 39 of the BTG1 breakpoint hotspot (primers
exon 2). Expression levels were normalized to HPRT levels, and compared to the expression level in Nalm6, which was set to 1. The data shown
represent the average of two independent cDNA reactions and triplicate qRT-PCR reactions.
doi:10.1371/journal.pgen.1002533.g003
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similar distribution over different cytogenetic subgroups in BCP-
ALL and were not present in T-ALL or normal bone marrow
samples. Moreover, in one patient, this subclonal BTG1 deletion-
positive clone at diagnosis reappeared as the major clone at
relapse, whereas in relapse samples of five other patients new
(sub)clonal BTG1 deletions appeared. These findings are com-
pletely in line with recent studies describing the clonal evolution of
ETV6-RUNX1 and BCR-ABL1 positive ALLs with a clonal
evolution during leukemia development showing that, upon
treatment, recurrent lesions occur repeatedly and independently
within a single patient, giving rise to a complex variety of slightly
different subclones [24,25]. Our current data provide additional
evidence for this model at the molecular level by showing that
BTG1 deletions arise independently in multiple ALL subclones in a
context-dependent manner.
In addition, our results provide insight into the genetic lesions
that act in concert with BTG1 deletions in BCP-ALL development.
We found, for example, that deletions in ETV6, EBF1 and RB1 co-
occur with BTG1 deletions, indicating that loss of normal BTG1
function may add to defects in pRb/E2F-mediated cell cycle and
EBF1-mediated B-cell differentiation pathways. Illegitimate RAG-
mediated recombination has been suggested as the responsible
mechanism for IKZF1 [19,20], CDKN2A/B [33,34] and LMO2
[35] deletions, as well as ETV6-RUNX1 translocations [30]. It
remains to be established whether RAG-mediated recombination,
or other mechanisms like CSR, are implicated in the occurrence of
RB1 and EBF1 deletions. However, similar to BTG1, these
recurrent gene deletions may repeatedly arise in different
subclones due to local subtype-specific accessibility of these loci
to specific recombination machineries, followed by clonal selection
and outgrowth.
In conclusion, our comprehensive analysis of BTG1 aberrations
revealed that this gene is recurrently and exclusively affected by
deletions in specific BCP-ALL subtypes. BTG1 deletions can arise
independently in different ALL subclones, which either develop
into a predominant clone at diagnosis, remain present as minor
subclones during the course of the disease, or develop into the
major clone at relapse. As such, this phenomenon may provide a
molecular explanation for the model of multiclonal evolution
during leukemogenesis.
Materials and Methods
Clinical Samples
A total of 831 patients diagnosed with BCP-ALL (n=722) and
T-ALL (n=109) were included in this study. Diagnosis samples
(n=831) and matched relapse samples (n=62) were collected by
the Dutch Childhood Oncology Group (DCOG) and the
Radboud University Nijmegen Medical Centre, the Netherlands.
Mononuclear cells were harvested through Ficoll gradient
separation and DNA was isolated using a QiaAmp purification
kit (Qiagen, Venlo, The Netherlands). DNA from non-leukemic
bone marrow samples was provided by Dr. Joop Jansen
(Department of Hematology, Radboud University Nijmegen
Medical Centre, the Netherlands). Written informed consent was
obtained for all patient and control samples.
Cell Lines
The human BCP-ALL (CCRF-SB, RS4;11, Nalm6, REH,
SUP-B15, 380, 697, SEM, TOM1, MUTZ5) and T-ALL cell lines
(MOLT4, Jurkat) were purchased either from ATCC or DSMZ.
T-ALL cell lines CML-T1, HSB2, and KARPAS45 were obtained
from Dr. Adolfo Ferrando (Columbia University, NY, USA) and
T-ALL cell line TK6 was obtained from Dr. Albert Fornace (NCI,
Bethesda, USA). Leukemia cell lines were maintained in RPMI-
1640 medium (Invitrogen) supplemented with 10% fetal calf
serum, 100 U/mL penicillin sodium, and 100 mg/mL of strepto-
mycin sulfate at 37uC in a humidified air atmosphere containing
5% carbon dioxide.
Multiplex Ligation-Dependent Probe Amplification
Leukemic patient samples and cell lines (380, 697, CCRF-SB,
RS4;11, SEM, TOM1, REH, MUTZ5, SUP-B15, Nalm6, Jurkat,
KARPAS45, MOLT4 and TK6) were analyzed for copy number
changes in BTG1 using multiplex ligation-dependent probe
amplification (MLPA). DNA was isolated using a QiaAmp
purification kit (Qiagen). A total of 9 probes was developed using
MeltIngeny software and guidelines provided by MRC-Holland
(Amsterdam, The Netherlands; Table S6). MLPA analyses were
performed using SALSA MLPA reaction mixture and P200-A1
reference probe-mix (MRC Holland) as previously described [5].
In addition, we determined the copy number status of several
leukemia-associated genes (PAX5, IKZF1, EBF1, CDKN2A,
CDKN2B, RB1, ETV6, BTG1) with the SALSA MLPA kit P335-
A2 ALL-IKZF1 (MRC Holland) according to manufacturer’s
instructions.
Bisulfite Sequencing
In 25 BCP-ALL patient diagnosis samples, we determined the
methylation status of the BTG1 promoter using bisulfite sequenc-
ing. A total of 500 ng DNA per sample was bisulphite converted
using the EZ DNA Methylation
TM Kit (Zymo research corpora-
tions, Leiden, The Netherlands) according to manufacturer’s
protocol. Subsequently, the CpG island was PCR amplified (for
primers see Table S7), cloned in a pGEM-T vector (Promega
Benelux BV, Leiden, The Netherlands), transformed in competent
E. Coli DH5a cells and plated on an LB agar plate containing
7 mg/ml ampicillin, 200 nM Isopropyl b-D-1-thiogalactopyrano-
side (IPTG) and 200 mg/ml X-Gal. After overnight incubation,
individual white clones were selected for colony PCR and
sequenced using a 3730 Sequence Analyzer (Applied Biosystems,
Foster City, CA, USA). Sequences were analyzed using Vector
NTI software (Advance TM 11.0, release December 15 2008,
Invitrogen, Breda, the Netherlands). In vitro methylated DNA was
used as a positive control. Briefly, 1 mg DNA was incubated with
4 U M.SssI CpG Methyltransferase (New England Biolabs,
Figure 4. Increased levels of H3K4me3 at the BTG1 locus in BCP-ALL versus T-ALL cell lines. (A) Quantitative real-time RT-PCR data
representing relative expression levels of BTG1 in T-ALL cell lines HSB2, Jurkat and KARPAS45, and BCP-ALL cell lines RS4;11, Nalm6 and CCRF-SB
(HPRT normalized and related to HSB2 expression levels). Data shown are the average of two independent cDNA reactions and triplicate qRT-PCR
reactions. (B and C) Percentage recovery after ChIP performed with H3K4me3 antibody (B) or H3K9/14Ac antibody (C) on T-ALL (HSB2, Jurkat,
KARPAS45) and BCP-ALL (RS4;11, Nalm6 and CCRF-SB) cell lines. Real-time quantitative PCR was performed with primers specific for the region 1 kb
upstream of the transcription start site (21 kb prom), directly flanking the transcription start site (prox prom), the second exon near the breakpoint
hotspot (exon 2) and towards the end of the 39untranslated region (39UTR) at the second (and last) exon of the human BTG1 gene. Values represent
two independent ChIP experiments. Student’s t-test was performed to assess differences between the average recovery of T-ALL versus BCP-ALL
samples. Asterisk (*) indicates a p-value,0.05.
doi:10.1371/journal.pgen.1002533.g004
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50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl2 and 1 mM
Dithiothreitol (pH7.9) for 4 hours at 37uC. As a negative control,
HEK293 DNA was amplified by using the GenomePlex Complete
Whole Genome Amplification Kit (Sigma-Aldrich, Zwijndrecht,
The Netherlands), according to manufacturer’s protocol.
BTG1 Mutation Detection
Sequencing of the first (n=135) and second (n=337) exon of
the BTG1 gene was performed on PCR-amplified exons using
flanking intron-based primers (listed in Table S7). PCR amplifi-
cations were performed with 10 ng DNA, 200 nM of each primer,
2 (ex1) or 2.5 (ex2) mM MgCl2, 200 mM dNTPs, 1 M GC melt
(Clontech, Saint-Germain-en-Laye, France), 106 PCR buffer II,
2.5 U AmpliTaq Gold (Applied Biosystems) using 5 minutes
preheating at 96uC, followed by 35 cycles of 30 seconds at
96uC, 30 seconds at 55.3uC and 1 min at 72uC, and termination
for 3 min at 72uC. The samples were sequenced using a 3730
Sequence Analyzer (Applied Biosystems) and the results were
analyzed using Vector NTI software (Invitrogen).
Genomic SNP Arrays
To characterize the BTG1 deletions in further detail, we
performed high-resolution copy number and genotyping analyses
using Affymetrix SNP6.0 arrays according to standard protocols
provided by the manufacturer. Genotypes were generated using
Affymetrix Genotyping Console v2.1 and Nexus 5.0 software
(BioDiscovery, Inc 2010, build version 4621). Normal copy
number variation was filtered out using data from our in-house
database (containing over 600 healthy control samples), Hapmap,
and the Database of Genomic Variants (http://projects.tcag.ca/
variation/).
Breakpoint Mapping and PCR-Based Validation
Starting from the SNP array data, we used a stepwise approach
to zoom in on eight individual breakpoints of different BTG1
deletions. We determined the exact genomic breakpoints and
interstitial sequences using Q-PCR, long-range PCR and finally,
standard PCR and sequencing. Q-PCR was performed on a
7900HT FAST Real-Time PCR system (Applied Biosystems) with
SYBR Green to detect PCR product. Long range PCR was
performed using TaKaRa La Taq (Takara Bio Inc, Otsu, Shiga,
Japan). PCR amplicons were sequenced using a 3730 Sequence
Analyzer (Applied Biosystems) and analyzed with VectorNTI
software (Invitrogen). The primer pairs used to detect and
sequence the eight different breakpoints are listed in Table S7.
For PCR-based validation we used 20 ng DNA, 200 nM of each
primer, 2 or 2.5 mM MgCl2, 200 mM dNTPs, 106PCR buffer II,
2.5 U AmpliTaq Gold (Applied Biosystems) using 5 minutes
preheating at 95uC, followed by 10 cycles of 30 seconds at
95uC, 2 min at 60uC or 57.8uC and 2 min at 72uC, and a further
30 cycles of 30 seconds at 95uC, 30 seconds at 60uC or 57.8uC
and 2 min at 72uC, and termination for 10 min at 72uC.
RT–PCR
Total RNA from the BCP-ALL and T-ALL cell lines was
extracted with Trizol (Invitrogen), while total RNA from diagnosis
patient samples was isolated using the RNeasy kit (Qiagen), both
according to the manufacturer’s instructions. Total RNA was
converted to cDNA via RT-PCR using random 6-mers and
Superscript III Reverse Transcriptase (Invitrogen). Thereafter,
cDNA was resolved in 50 ml ddH2O, and PCR amplifications
were performed in 30 ml reactions at standard concentrations
(1.5 mM MgCl2, 0.2 mM dNTP, 16PCR buffer (Invitrogen), 2 U
Platinum Taq (Invitrogen), 0.3 mM of each primer, and 2 ml
cDNA template) (see Table S7 for primer sequences). PCR
reactions were performed for 35 cycles at an annealing
temperature of 58uC using an Eppendorf Mastercycler. The
PCR fragments obtained were resolved by 1% agarose gel
electrophoresis, isolated using Qiagen gel extraction kit and
cloned into pGEM-T easy for sequencing with M13 primers.
Quantitative real-time PCR was performed to determine the
expression of BTG1 mRNA sequences 59 to the breakpoint hotspot
(exon primers flanking intron 1), BTG1 exon 2 (primers flanking
breakpoint hotspot) and HPRT with Power SYBR Green (Applied
Biosystems) (Table S7). Reactions were performed in triplicate on
two independent cDNA templates using an Applied Biosystems
7500 Real-Time PCR thermocycler (ABI). Data were represented
as fold differences relative to BTG1 mRNA expression in Nalm6
cells normalized to HPRT expression based on calculation of
2
2DDCt.
Cloning and Protein Expression Analyses BTG1
Constructs
HA-BTG1-Trunc was generated by PCR based on full-length
HA-BTG1 [8], using primers indicated in Table S7. PCR
products were purified, cloned into the EcoRI and XhoI sites of
pcDNA3.1 (Invitrogen) and verified by Sanger sequencing. To
analyze protein expression of the different BTG1 constructs,
HEK293 cells were transfected with 10 mg of plasmid DNA using
linear Polyethyleneimine (PEI, Polysciences, Warrington, PA). The
next day cells were splitted over two dishes and, 24 hours after
transfection, treated with 5 mM MG132 (Peptides International,
Louisville, KY) in DMSO or vehicle for 16 hours. For detection of
HA-BTG1 protein expression, 5610
6 cells were lysed in Laemmli
sample buffer containing 2% SDS and 100 mM DTT, boiled for
5 minutes, loaded on 15% SDS-PAGE, blotted on PVDF
membrane, and stained with HA antibody, clone 3F10 (Roche
Diagnostics). Protein expression was visualized using ECL Plus
Western Blot Detection System (GE Healthcare) and FluorchemE
digital imaging device (Cell Biosciences).
Chromatin Immunoprecipitations
After crosslinking for 15 min with 1% formaldehyde, the
leukemia cells were re-suspended in ice-cold lysis buffer (50 mM
HEPES [pH7.6], 140 mM NaCl, 1 mM EDTA, 1% Triton X-
100, 0.1% Sodium Deoxycholate) supplemented with Complete
protease inhibitors (Roche) at a density of 35610
6 cells/mL and
sonicated for 15 min, 30 seconds on and 30 seconds off (Bioruptor
Diagenode). Chromatin was incubated overnight in the presence
0.1% BSA, 20 mM HEPES (pH 7.6), 150 mM NaCl, 1 mM
EDTA, 0.5 mM EGTA, 0.15% SDS, 1% Triton X-100, protein
A/G beads (Santa Cruz), Complete protease inhibitors and 2 mg
H3K4me3 or H3K9/14Ac antibody (both from Diagenode).
Beads were washed two times in buffer 1 (0.1% SDS, 0.1%
Sodium Deoxycholate, 1% Triton X-100, 150 mM NaCl, 1 mM
EDTA, 0.5 mM EGTA, 20 mM HEPES [pH7.6]), one time in
buffer 2 (0.1% SDS, 0.1% Sodium Deoxycholate, 1% Triton X-
100, 500 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 20 mM
HEPES [pH7.6]), one time in buffer 3 (0.5% Sodium Deoxycho-
late, 0.5% NP40, 250 mM LiCl , 1 mM EDTA, 0.5 mM EGTA,
20 mM HEPES [pH7.6]), and two times in buffer 4 (1 mM
EDTA, 0.5 mM EGTA, 20 mM HEPES [pH 7.6]). Chromatin
was eluted from the beads with 1% SDS/100 mM NaHCO3 and
de-crosslinked together with input material for 4 hrs at 65uC with
200 mM NaCl. After phenol:chloroform:isoamylalcohol extrac-
tion, DNA was precipitated in the presence of 10 mg glycogen.
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using Power SYBR Green (Applied Biosystems) and an Applied
Biosystems 7500 Real-Time PCR thermocycler (primers are listed
in Table S7). The percentage recovery was equal to dilution factor
of input DNA62
(Ct Input-Ct ChIP)6100.
Statistical Analyses
Co-occurrence of copy number alterations and cytogenetic
subgroups was compared using crosstabs and a standard chi-square
test or Fisher’s exact test when sample groups were small. The
differences between H3K4me3 and H3K9/14Ac levels in T-ALL
versus BCP-ALL samples was assessed using a Student’s t-test.
Statistical analyses were carried out using the SPSS statistical package
(IBM,Chicago, IL, USA; release 16.0.2, April 2008) and two-sided P-
values below 0.05 were considered to be statistically significant.
Supporting Information
Figure S1 BTG1-Trunc protein levels are highly unstable and
expressed at extremely low levels. (A) Schematic representation of
the full length BTG1 protein and deletion mutant BTG1-Trunc,
which mimics the common deletion variant observed in BCP-ALL
harboring monoallelic BTG1 deletions. The conserved BoxA,
BoxB and BoxC domains as well as the nuclear hormone receptor
interaction residues LxxLL are indicated. (B) Immunoblot shows
BTG1 protein levels from pcDNA3.1 vectors expressing HA-
BTG1 (WT) and HA-BTG1-Trunc (Tr) upon transfection in
HEK293 cells in the absence or presence of 5 mM MG132 for
16 hrs. Protein expression is detected with HA antibody 3F10. (C)
BTG1 RNA expression levels in the same pool of transfected
HEK293 cells: Real-time PCR was performed on cDNA
generated in the absence (black bars) or presence (grey bars) of
Reverse Transcriptase (RT). BTG1 expression was normalized to
expression levels of the basal transcription factor TBP.
(PDF)
Figure S2 Monoallelic BTG1 deletions result from aberrant
RAG-mediated recombination. The recombination signal se-
quence (RSS) consists of a conserved 7-bp sequence (heptamer;
consensus CACAGTG), a 9-bp sequence (nonamer consensus
ACAAAAACC), and an intervening, non-conserved 1261o r
2361 bp spacer sequence. Recombination that takes place
between RSS found in the opposite chromosomal orientation will
result in deletion of the intervening DNA sequences. Joining of the
RAG-mediated double-strand breaks is carried out by the non-
homologous DNA end-joining (NHEJ) proteins via the concerted
action of the Ku70/80 proteins, DNA-dependent protein kinase
(DNA-PK), Artemis, XRCC4, DNA Ligase 4 (Lig4) and terminal
deoxynucleotidyl transferase (TdT). RAG-mediated recombina-
tion results in the formation of a precise signal joint and modified
coding joint. (A) Schematic representation of the human B cell
receptor IgH locus, with the number of gene segments indicated
above the V, D and J gene loci. V(D)J recombination occurs only
between two gene segments flanked, respectively, by 12-bp RSS
and a 23-bp RSS, referred to the 12/23 rule. Thus, the 12/23 rule
prohibits direct VH-to-JH joining. (B) Schematic representation of
the human BTG1 gene on chromosome 12, which contains a 23-
bp RSS at the deletion hotspot in the second exon, and one of the
seven identified distal deletion breakpoints harboring a 12-bp
RSS. RAG-induced recombination results in deletion of the
intervening DNA and a modified coding joint at the BTG1 gene,
where TdT adds random, non-templated nucleotides.
(PDF)
Table S1 BTG1 microdeletions co-occur with deletions in
recurrently affected genes in BCP-ALL.
aBecause of missing
values, numbers do not always add up to 722 BCP-ALL cases.
(PDF)
Table S2 BTG1 deletion breakpoint sequences in BTG1 MLPA
deletion-positive BCP-ALL cases and cell lines. Sequencing of
intragenic BTG1 deletions demonstrates the presence of (near)
consensus DNA sequence motifs for V(D)J recombination flanking
the breakpoint hotspot in exon 2 of BTG1 and the distal
breakpoint clusters. The consensus heptamer RSS [CAC(A/
T)(A/G)(C/T)(A/G) on (+) strand and (C/T)(A/G)(C/T)(A/
T)GTG on (-) strand] is shown in red and bold. Mismatches from
consensus are underlined. Single nucleotide mutations are
indicated in grey. The nucleotides inserted between the proximal
BTG1 and the distal breakpoints are indicated.
(PDF)
Table S3 Number of unique BTG1 deletion-spanning sequences
in the BTG1 MLPA deletion-positive BCP-ALL cases and cell
lines.
(PDF)
Table S4 Subclonal BTG1 microdeletion occurrence within the
cytogenetic subgroups. All patients screened were BTG1 deletion-
negative as determined by MLPA. Subclonal BTG1 deletion status
was determined using the PCR-based detection of deletions III, V
and VIII.
aBecause of missing values, numbers do not always add
up to 89 BCP-ALL cases. Data was available for 77 cases on
hyperdiploidy; 41 cases for ETV6-RUNX1; 60 cases for BCR-ABL1;
74 cases for MLL-rearrangement.
bThe other subgroup encom-
passes cases negative for ETV6-RUNX1, MLL, BCR-ABL1
translocations and/or hyperdiploidy. This group does not contain
any E2A-PBX1 translocation cases.
cSubgroup unknown includes
all cases in which no data is available in one or more cytogenetic
subgroups.
dFisher’s exact test was used when sample groups were
small.
(PDF)
Table S5 BTG1 fusion transcript sequences detected in inde-
pendent subclones. Deletion spanning sequence was confirmed by
sequencing of genomic DNA of the same case.
(PDF)
Table S6 MLPA probes for copy-number analysis of the BTG1
gene region. Universal M13 PCR primers are indicated in bold.
(PDF)
Table S7 Primers used for BTG1 bisulfite sequencing, mutation
screening, breakpoint mapping, expression analysis and CHIP
assay.
(PDF)
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